New AI model can detect multiple cognitive brain diseases from a single blood sample
protein
| Source: Mastodon | Original article
A research team at Sweden’s Karolinska Institute has unveiled a deep‑learning model that can pinpoint several neurodegenerative disorders from a single blood draw. By feeding the algorithm mass‑spectrometry data on thousands of protein fragments, the system learns to recognise the subtle, disease‑specific signatures that differentiate Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis and frontotemporal dementia in one go. In a validation set of 3,200 participants, the model achieved an average sensitivity of 92 % and specificity of 89 % across the four conditions, outperforming conventional biomarker panels that typically require separate assays for each disease.
The breakthrough matters because current diagnostics rely on expensive brain imaging, lumbar puncture or symptom‑based assessments that often arrive late in the disease course. A blood‑based, multiplexed test could shift detection to the primary‑care level, enabling earlier therapeutic intervention, better patient stratification for clinical trials, and a substantial reduction in healthcare costs. Moreover, the approach demonstrates how AI can extract clinically relevant patterns from high‑dimensional proteomic data that elude traditional statistical methods, opening a pathway for similar multiplexed screens in oncology and metabolic disorders.
The next steps will determine whether the technology moves from the lab to the clinic. The team plans a multicentre prospective trial in Norway, Denmark and Finland later this year to confirm performance in diverse populations and to assess longitudinal predictive power. Regulators will scrutinise the algorithm’s transparency and the reproducibility of its protein‑signature database, while commercial partners are already courting the group for assay development. Watch for announcements on trial enrollment, potential FDA or EMA filings, and how the model stacks up against rival AI‑driven diagnostics emerging from DeepSeek and other European biotech hubs.
Sources
Back to AIPULSEN